Thwe MYA 96.

Methods	Randomised, method not specified No exclusions reported Loss to follow‐up at day 28: AS1200 = 0/27, AS800 = 2/27 (7%)
Participants	54 Burmese male adults 18 to 50 years Clinical features of severe (Glasgow scale 10‐14) and complicated falciparum malaria (WHO 1990b) Excluded: concomitant illness; haemorrhoids; gastrointestinal problems or previous rectal surgery; mixed malaria infection; antimalarials in previous 14 days
Interventions	ASpr800 + MQ25 vs ASpr1200 + MQ25: 1. AS 800 mg (200 mg at 0 h, 12 h, 24 h and 36 h) + MQ 1250 mg (sequential, 750 mg at 48 h, 500 mg at 60 h) 2. AS 1200 mg (200 mg at 0 h,12 h, 24 h, 36 h, 48 h and 60 h) + MQ 1250 mg (sequential, 750 mg at 72 h, 500 mg at 84 h)
Outcomes	1. Mortality 2. FCT 3. PCT 4. Recrudescence at day 28 5. Side effects (haematological & biochemical laboratory tests)
Notes	Quality assessment: B, B, A Plasmotrim, Rectocaps 200 mg capsule, Mepha